Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00052468
Status:
COMPLETED
Last Update Posted:
2014-06-25
First Post:
2003-01-24
Brief Title:
CarboplatinPaclitaxel -Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer
Sponsor:
AGO Study Group
Organization:
AGO Study Group
Study Overview
Official Title:
A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With GemcitabinePaclitaxelCarboplatin vs PaclitaxelCarboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV
Status:
COMPLETED
Status Verified Date:
2014-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AGO-OVAR9
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Combining more than one drug may kill more tumor cells It is not yet known whether carboplatin and paclitaxel combined with gemcitabine is more effective than carboplatin and paclitaxel alone in treating ovarian epithelial or fallopian tube cancer
PURPOSE This randomized phase III trial is studying carboplatin and paclitaxel combined with gemcitabine to see how well it works compared to paclitaxel and carboplatin alone in treating patients who have undergone surgery for ovarian epithelial or fallopian tube cancer
PURPOSE This randomized phase III trial is studying carboplatin and paclitaxel combined with gemcitabine to see how well it works compared to paclitaxel and carboplatin alone in treating patients who have undergone surgery for ovarian epithelial or fallopian tube cancer
Detailed Description:
OBJECTIVES
Compare overall survival in patients with stage I-IV ovarian epithelial or fallopian tube cancer treated with adjuvant carboplatin and paclitaxel with or without gemcitabine
Compare response rates progression-free survival and duration of response in patients treated with these regimens
Compare toxic effects of these regimens in these patients
Compare quality of life of patients treated with these regimens
OUTLINE This is a randomized open-label controlled multicenter study Patients are stratified according to FIGO stage I-IIA vs IIB-IIIC and tumor no greater than 10 mm vs IIB-IIIC and tumor greater than 10 mm or IV plan for interval surgical debulking yes vs no and participating center Patients are randomized to 1 of 2 treatment arms
Arm I Patients receive carboplatin IV over 30-60 minutes and paclitaxel IV over 3 hours on day 1 and gemcitabine IV over 30-60 minutes on days 1 and 8
Arm II Patients receive carboplatin and paclitaxel as in arm I Treatment in both arms repeats every 21 days for 6 to 10 courses in the absence of disease progression or unacceptable toxicity
Some patients undergo interval debulking surgery
Quality of life is assessed at baseline after courses 3 and 6 and then at 3 6 and 12 months after completion of study
Patients are followed every 3 months for 2 years every 6 months for up to 5 years and then annually thereafter
PROJECTED ACCRUAL A total of 1716 patients 858 per treatment arm will be accrued for this study within 2 years
Compare overall survival in patients with stage I-IV ovarian epithelial or fallopian tube cancer treated with adjuvant carboplatin and paclitaxel with or without gemcitabine
Compare response rates progression-free survival and duration of response in patients treated with these regimens
Compare toxic effects of these regimens in these patients
Compare quality of life of patients treated with these regimens
OUTLINE This is a randomized open-label controlled multicenter study Patients are stratified according to FIGO stage I-IIA vs IIB-IIIC and tumor no greater than 10 mm vs IIB-IIIC and tumor greater than 10 mm or IV plan for interval surgical debulking yes vs no and participating center Patients are randomized to 1 of 2 treatment arms
Arm I Patients receive carboplatin IV over 30-60 minutes and paclitaxel IV over 3 hours on day 1 and gemcitabine IV over 30-60 minutes on days 1 and 8
Arm II Patients receive carboplatin and paclitaxel as in arm I Treatment in both arms repeats every 21 days for 6 to 10 courses in the absence of disease progression or unacceptable toxicity
Some patients undergo interval debulking surgery
Quality of life is assessed at baseline after courses 3 and 6 and then at 3 6 and 12 months after completion of study
Patients are followed every 3 months for 2 years every 6 months for up to 5 years and then annually thereafter
PROJECTED ACCRUAL A total of 1716 patients 858 per treatment arm will be accrued for this study within 2 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EU-20241 | None | None | None |
| AGO-OVAR9 | None | None | None |
| NORDIC-AGO-OVAR-9 | None | None | None |
| GERCOR-AGO-OVAR-9 | None | None | None |